AI's New Clarity: How FDA-Cleared Tech Aims to Reshape Dementia Diagnosis

COVINGTON, Ky. – August 18, 2026 – For decades, the diagnosis of Alzheimer’s disease has been a journey through a fog of uncertainty, often relying on cognitive tests and the exclusion of other conditions. But a new tool, powered by artificial intelligence, aims to provide a beacon of quantitative clarity. Today, Cortechs.ai announced it has received FDA 510(k) clearance for NeuroQuant® PET, a software platform designed to bring objective, standardized measurement to the interpretation of brain scans for cognitive impairment.

This clearance represents more than just a new piece of software; it signals a critical shift in how we approach neurodegenerative disease. By moving from symptom-based assessment to a biological, biomarker-driven model, technologies like this are forcing a necessary conversation about the architecture of our dementia care systems, the promise of precision medicine, and the deeply human experience of receiving a life-altering diagnosis.

From Subjective Guess to Objective Data

At its core, NeuroQuant® PET is designed to solve a fundamental problem in medical imaging: variability. When a patient undergoes a Positron Emission Tomography (PET) scan to look for the telltale amyloid plaques associated with Alzheimer’s, the interpretation has historically involved a degree of subjectivity. A radiologist’s reading in one hospital might differ slightly from another's.

Cortechs.ai’s newly cleared software automates this process. It analyzes PET scans and provides standardized, numerical values—specifically, Standardized Uptake Value Ratios (SUVRs) and a score on the “Centiloid” scale. This creates a common language for measuring amyloid burden in the brain, making results comparable across different scanners, different hospitals, and even different amyloid-detecting tracers. The goal is to replace a qualitative assessment (“there appears to be significant plaque”) with a quantitative one (“the Centiloid score is 65”).

This shift is what experts call the move from phenotype (symptoms) to biology (biomarkers). As Dr. Ana Franceschi, M.D., Ph.D., noted in the announcement, “Automated quantitative PET imaging represents the next frontier in precision and personalized medicine for Alzheimer’s disease and related neurocognitive disorders.” The technology promises to give clinicians reproducible data they can trust, potentially leading to earlier, more confident diagnoses.

The FDA’s 510(k) clearance pathway, used for most low-to-moderate risk devices, confirms that NeuroQuant® PET is substantially equivalent to a legally marketed predicate device. This frames it not as an autonomous diagnostician, but as a powerful aid for physicians, intended to augment—not replace—their clinical judgment.

A Strategic Piece in a Larger Puzzle

The clearance is also a significant strategic move for Cortechs.ai, solidifying its position as a key architect in the technological infrastructure of modern dementia care. This is not the company's first foray into neuro-imaging AI. Its existing NeuroQuant® suite for MRI scans is already used by clinicians to measure brain volume changes, a key indicator of neurodegeneration.

More recently, the company developed tools to specifically identify and quantify Amyloid Related Imaging Abnormalities (ARIA)—a type of brain swelling or bleeding that is a known side effect of the new class of anti-amyloid therapies for Alzheimer’s. With NeuroQuant® PET, the company now offers a more complete ecosystem: one set of tools to help diagnose the disease by quantifying amyloid, and another set to monitor the safety of the very drugs designed to treat it.

“NeuroQuant® PET reflects our commitment to advancing quantitative imaging in dementia care, giving clinicians objective, reproducible measurements they can trust, so patients get earlier answers and more confident treatment decisions,” said Kyle Frye, CEO of Cortechs.ai. This integrated approach positions the company to be an indispensable partner for neurology clinics and pharmaceutical companies navigating the new era of disease-modifying treatments.

This technology does not exist in a vacuum. It enters a dynamic landscape that includes emerging blood tests for Alzheimer's, which promise a cheaper and more accessible way to screen large populations. However, industry observers believe imaging will remain the gold standard for confirmation. As one analyst noted, blood tests will likely identify more candidates for further evaluation, but quantitative imaging like NeuroQuant® PET will be crucial for confirming eligibility for treatment, establishing a baseline, and monitoring the disease over time.

The Human Equation: Promise and Peril of Early Answers

Beyond the technology and business strategy lies the most important question: what does this mean for people? The promise of an early, definitive diagnosis is profound. For patients and their families, it can end a long and agonizing “diagnostic odyssey,” providing a clear name for the thief stealing memories and cognitive function.

An early diagnosis unlocks the potential for early intervention. It allows families to plan for the future—legally, financially, and emotionally. Critically, it is the key that opens the door to new disease-modifying therapies, which are most effective when started in the earliest stages of the disease. As patient advocacy groups have long argued, having this information empowers individuals and families to make crucial decisions about care and to seek out support networks.

Yet, this promise is shadowed by significant challenges for both individuals and the healthcare system. The psychological weight of receiving a diagnosis for an incurable neurodegenerative disease, perhaps years before severe symptoms manifest, can be immense. It raises the ethical dilemma of the “right to know” when a cure remains elusive. Comprehensive mental health support must become a non-negotiable component of the diagnostic process.

Furthermore, access remains a formidable barrier. PET scanners are expensive and not uniformly available, particularly in rural and underserved communities. Even with an accurate diagnosis, navigating the labyrinth of insurance coverage for these new technologies and the costly treatments they enable can be overwhelming. This creates a risk of a two-tiered system of dementia care, where those with resources get early answers and access to cutting-edge therapies, while others are left behind.

The healthcare system itself is not yet fully prepared for the downstream effects of such powerful diagnostic tools. A surge in early diagnoses requires a corresponding surge in neurologists, geriatric specialists, care managers, and support services—a workforce we do not currently have. This technology is a powerful instrument, but its ultimate value will be determined by our collective ability to build a compassionate, equitable, and robust system of care around it.